Research Library

Republicans are ready to support Israel. But what about Ukraine? As the war between Israel and Hamas intensifies, fellow Joe Barnes examines the shifting focus of U.S. foreign policy and what it means for Kyiv.

In the fight against Mexican criminal cartels, social network analysis can predict and map out their alliances and subgroups — using algorithms to predict new connections. In this commentary, Nonresident Scholar in Drug Policy and Mexico Studies Nathan P. Jones and his co-authors outline their recent work in the field.

Federal marijuana legalization is on the horizon — and it’s time for the DEA to get behind the policy changes and move on to fighting more dangerous drugs, writes nonresident fellow Gary Hale.

Where do the GOP presidential hopefuls stand on major foreign policy issues? Bonner Means Baker Fellow Joe Barnes explores the Republican candidates’ likely policy approaches to the Ukraine war, Chinese expansionism, fentanyl at the border and more.

Decades of bad policy have heightened the risks of drug use and created barriers to treatment. And while some states are now trying to reduce the harms caused by the drug war, Texas is doubling down on ineffective policies.

Mexican President Andrés Manuel López Obrador's deference to drug cartels in Mexico reveals that he is not interested in meaningful cooperation on bilateral drug law enforcement, and his administration should be regarded as hostile to U.S. interests, writes nonresident fellow Gary Hale.

The rapid adoption of telemedicine is one of the few positive developments of the COVID-19 pandemic, writes fellow Katharine Neill Harris. She explains why the DEA’s recent proposal to change the rules for prescribing drugs via telemedicine would harm patients and increase demand for and exposure to unregulated and more dangerous drugs.

In 2022, the nation faced fundamental questions about how we govern our economy and society — particularly how we formulate public policy. Here, we share 10 highlights of our work that illustrate our impact from the previous year.

Drug companies that bypass distributors and offer generics directly to patients, like the Mark Cuban Cost Plus Drug Company, could disrupt the pharmaceutical supply chain and ultimately save thousands of lives.